Advertisement

Moderna Begins Trial Of 'Next-Gen Booster' Covid Vax

Follow The Hawk on Google News+ Follow

Advertisement


New York: Biotechnology company Moderna announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the company's next generation Covid-19 vaccine candidate.

This Phase 1 dose-ranging study will assess the safety and immunogenicity of mRNA-1283, the company said in a statement.

Advertisement

"We are pleased to begin this Phase 1 study of our next generation COVID-19 vaccine candidate, mRNA-1283," said St?phane Bancel, Chief Executive Officer of Moderna.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

"Our investments in our mRNA platform have enabled us to develop this next generation vaccine candidate, which is a potential refrigerator-stable vaccine that could facilitate easier distribution and administration in a wider range of settings, including potentially for developing countries," Bancel added.

mRNA-1283 encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and N-terminal Domain (NTD). This Phase 1 study will evaluate three dose levels, 10 ug, 30 ug, and 100 ug, of the mRNA-1283 vaccine candidate given to healthy adults as a 2-dose series, 28 days apart, and one dose level, 100 ug, of mRNA-1283 given to healthy adults in a single dose, the company said.

These will be compared with a 2-dose series of 100 ug of mRNA-1273, the currently authorised dose level. mRNA-1283 is intended to be evaluated in future studies for use as a booster dose for previously vaccinated or seropositive as well as in a primary series for seronegative individuals. —IANS

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST